SCHEMBL320610

SCHEMBL320610

C[C@H](O)C(=O)OCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
TDP1 Q9NUW8 2/20 0.55
MAPK1 P28482 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A3 Q01959 1/20 0.55
KMT2A Q03164 1/20 0.55
LMNA P02545 2/20 0.50
HCAR2 Q8TDS4 1/20 0.50
ATM Q13315 1/20 0.49
CTSB P07858 1/20 0.48
CTSL P07711 1/20 0.48
CTSS P25774 1/20 0.48
LTA4H P09960 1/20 0.48
LAP3 P28838 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1107604 1.00 ALDH1A1 (0.62) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL201855 1.00 ALDH1A1 (0.62) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL21688461 0.88 ALDH1A1 (0.53) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL5400343 0.88 ALDH1A1 (0.56) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL10165250 0.88 ALDH1A1 (0.53) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL5400346 0.88 ALDH1A1 (0.56) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL18651131 0.88 ALDH1A1 (0.53) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
Valine SCHEMBL28307488 0.87 SLC15A1 (0.58) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL24859302 0.86 ALDH1A1 (0.51) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL21688727 0.86 ALDH1A1 (0.51) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117720550-A Synthesis method of (S) -3-methyl-4-oxo-2-oxa-8-azaspiro [4.5] decane-8-carboxylic acid tert-butyl ester 深圳市华先医药科技有限公司 2024-03-19 CN claimed
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-23 US disclosed
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof SYSTIMMUNE, INC. (US) 2026-03-17 US disclosed
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 US disclosed
US-12478696-B2 Gadolinium chelate compounds for use in magnetic resonance imaging BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-11-25 US disclosed
EP-4619048-A1 CYCLEN BASED COMPOUNDS AND THEIR GD(III) COMPLEXES FOR USE AS MULTIMODAL PET/MRI CONTRAST AGENTS Ustav Organicke Chemie a Biochemie AV CR v.v.i. (CZ) 2025-09-24 EP disclosed
EP-3676265-B1 METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES ELANCO ANIMAL HEALTH GMBH (DE) 2025-08-20 EP disclosed
EP-4595978-A1 ANTI-CD33 ANTIBODY AND ANTI-CD33 ANTIBODY-DRUG CONJUGATE AND USE THEREOF SystImmune, Inc. (US) 2025-08-06 EP disclosed
US-20250205349-A1 ANTI-HUMAN TROP2 ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND MEDICAL USE THEREOF SYSTIMMUNE, INC. 2025-06-26 US disclosed
US-5002692-A Amide liquid crystal compounds: mixtures and devices using them THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1991-03-26 US disclosed
EP-0258298-B1 LIQUID CRYSTAL COMPOUNDS CONTAINING TWO OR MORE CHIRAL CENTERS SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOV. OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1990-08-29 EP disclosed
US-4923633-A Liquid crystal compounds containing two or more chiral centers THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1990-05-08 US disclosed
EP-0201578-B1 ALPHA-HYDROXY CARBOXYLIC ACID DERIVATIVES SUITABLE FOR USE IN LIQUID CRYSTAL MATERIALS AND DEVICES The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) 1989-11-02 EP disclosed
US-4852977-A 19 -hydroxy carboxylic acid derivatives suitable for use in liquid crystal materials and devices THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1989-08-01 US disclosed
EP-0301021-A1 AMIDE LIQUID CRYSTAL COMPOUNDS: MIXTURES AND DEVICES USING THEM. SECR DEFENCE BRIT (GB) 1989-02-01 EP disclosed
EP-0258298-A1 LIQUID CRYSTAL COMPOUNDS CONTAINING TWO OR MORE CHIRAL CENTERS. SECR DEFENCE BRIT (GB) 1988-03-09 EP disclosed
WO-1987005896-A1 AMIDE LIQUID CRYSTAL COMPOUNDS: MIXTURES AND DEVICES USING THEM THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) 1987-10-08 WO disclosed
WO-1987004705-A2 LIQUID CRYSTAL COMPOUNDS CONTAINING TWO OR MORE CHIRAL CENTERS THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) 1987-08-13 WO disclosed
CN-85109025-A The liquid-crystal composition that contains the alpha-hydroxy carboxylic acid compounds derivative 1986-09-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS HCRTR2, HCRTR1, CNR1 ALDH1A1 1750/4885TDP1 4616/4885MAPK1 2000/4885
US-12478696-B2 Gadolinium chelate compounds for use in magnetic resonance imaging GLRA1, GLRA3, GLRB ALDH1A1 3811/4885TDP1 1272/4885MAPK1 1678/4885
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof IGLV6-57, EGFR, ERBB2 ALDH1A1 3799/4885TDP1 1675/4885MAPK1 2880/4885
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4701/4885TDP1 1427/4885MAPK1 2993/4885
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4718/4885TDP1 1688/4885MAPK1 3012/4885
US-20250205349-A1 ANTI-HUMAN TROP2 ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND MEDICAL USE THEREOF TOP2A, TPM4, TPM3 ALDH1A1 759/4885TDP1 134/4885MAPK1 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.